Presented by
Management Forum

Advanced Pharmacovigilance

This course will be of maximum benefit to those drug safety professionals who are working both in the clinical and post-marketing safety arena including QA for auditing.

1-3 Dec 2021 + 4 more dates

Enrol now

  • Format: Classroom, Live online
  • CPD: 18 hours for your records
  • Certificate of completion

Course overview

Pharmacovigilance has undergone rapid regulatory change in recent years, which has resulted in a complex range of safety and risk assessment activities to perform. This three-day course is designed for those with at least two years’ knowledge in drug safety and will provide a comprehensive, yet practical assessment of the main regulations required to produce a compliant reporting company.

Key topics to be addressed:

  • Audits and expectations – risk-based inspections
  • Compliance and drug safety
  • Overview of the PSMF in the EU
  • Product safety reviews – purpose and function (incorporating the latest EU signal analysis requirements)
  • Safety reporting in licensing agreements
  • Developing company core safety information (CCSI) – CIOMS III
  • PSURs – timing, content and the DSUR and the latest ICH E2C (2nd revision requirements)
  • Implications for safety reporting in global clinical trials
  • Risk-benefit determinations
  • Risk management plans (RMPs)


By attending this event, you will:

  • Expand your global safety knowledge
  • Enhance your team’s capabilities and compliance in both the regulations and your company’s expectations
  • Help ensure you build and maintain a quality pharmacovigilance department ready for any pharmacovigilance inspection
  • Participate in group workshop sessions and discuss how to apply the legislation to ensure compliance, especially to satisfy regulatory inspections

Who should attend?

This course would be of maximum benefit to those safety professionals who are working both in the clinical and post–marketing safety arena including QA for auditing. The course covers very diverse activities within the safety department and would be advantageous to those who have either multifunction responsibilities or medical directors who manage teams in the various disciplines.

Enrol now

The Advanced Pharmacovigilance course will cover:

Due diligence

  • Due diligence on products/companies (partners and acquisitions)
  • Due diligence involvement – team composition
  • Safety information requirements for due diligence
  • Review of safety data (clinical and post-marketing)
  • Defining risk in due diligence appraisals

Training for drug safety reporting duties

  • Regulations concerning safety training
  • Who trains whom and when?
  • Training versus job description
  • Training records, maintenance and updates
  • Role of QA and HR in training

Audits and expectations

  • Regulatory expectations in pharmacovigilance audits (risk-based inspections)
  • Preparation for the audit
  • Records to be available at the audit
  • Audit findings/recommendations

Compliance and drug safety

  • Basic principles – what will the regulators want to see?
  • Measuring compliance
  • Quality versus quantity in safety reports
  • Future aspects in ensuring efficient compliance
  • Quality management under the new EU legislation

The PSMF

  • The PSMF – purpose and maintenance
  • The PSMF annexes
  • The PSMF and audits

Interactive exercise: The requirements for a safety department

Product safety reviews – purpose and function

  • The Safety Review Committee (SRC)
  • What to look for in signal evaluation under latest EU guidance
  • Timings for safety review in clinical and post-marketed products
  • Record keeping for safety review meetings
  • Serious safety findings – crisis management following new safety findings

Interactive exercise: Designing the requirements for a safety review group

Safety reporting in licensing agreements

  • What types of licensing agreements exist?
  • What are the EU and FDA regulations concerning licensing agreements?
  • Audits of pharmacovigilance capabilities in licensing partners
  • What agreements need to be in place for safety reporting?
  • Safety reporting agreements – what needs to be covered?
  • Monitoring safety agreements – what happens if it goes wrong?

Developing CCSI – CIOMS III

  • CIOMS III and CCSI
  • Developmental core safety information (DCSI)
  • How to determine what to include and what to exclude in DCSI/CCSI
  • Are there differences in EU and FDA?
  • Maintenance and development of CCSI

Interactive exercise: Should new safety data from a clinical trial be put into core safety information?

PSURs and the revisions in ICH E2C

  • Timing for PSURs
  • PSUR content and latest format
  • Late breaking information and PSUR extensions
  • The DSUR

The EU Clinical Trials Directive

  • The principles of the Directive
  • Implications for safety reporting in global clinical trials
  • The SUSAR database
  • The EUDRACT database
  • The new EU Clinical Trial Regulation

Risk-benefit determinations

  • Definitions of risk-benefit – FDA and EU perspective
  • Risk-benefit assessments – who does this and where does the information go?
  • Safety assessments and risk-benefit – frequency and reporting
  • Changes in risk-benefit – how to manage and review existing profiles

Interactive exercise: Reviewing the safety and risk-benefit of a product

RMPs

  • Purpose
  • Content
  • Monitoring and updating the RMP
  • Reporting the RMP

Crisis management within drug safety

  • Regulations and guidelines in connection with serious safety issues
  • What determines a crisis?
  • Communications to regulators – what is required?
  • Communications within the company
  • What happens next?

Interactive exercise: Deciding how to handle a major crisis within the company

Delegates will be split into groups and present what they need to have in place in order to effectively manage the crisis and look to its resolution.


Enrol now

Graeme Ladds

Graeme Ladds, Director of PharSafer, has over 30 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

More details

Book Advanced Pharmacovigilance Classroom/Live online training

1-3 Dec 2021

Classroom
London venue TBC

09:00-17:00 UK (London)
Course code 11377

  • GBP 1,549 1,849
  • EUR 2,169 2,589
  • USD 2,416 2,884

Until 27 Oct

  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

In your basket 

1-3 Mar 2022

Live online

09:30-17:00 UK (London) (UTC+00)
10:30-18:00 Paris (UTC+01)
04:30-12:00 New York (UTC-05)
Course code 11580

  • GBP 1,249 1,549
  • EUR 1,809 2,229
  • USD 2,056 2,524

Until 25 Jan

In your basket 

7-9 Jun 2022

Classroom
London venue TBC

09:00-17:00 UK (London)
Course code 11875

  • GBP 1,549 1,849
  • EUR 2,169 2,589
  • USD 2,416 2,884

Until 03 May

  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

In your basket 

21-23 Sep 2022

Live online

09:30-17:00 UK (London) (UTC+01)
10:30-18:00 Paris (UTC+02)
04:30-12:00 New York (UTC-04)
Course code 11696

  • GBP 1,249 1,549
  • EUR 1,809 2,229
  • USD 2,056 2,524

Until 17 Aug

In your basket 

7-9 Dec 2022

Classroom
London venue TBC

09:00-17:00 UK (London)
Course code 11948

  • GBP 1,549 1,849
  • EUR 2,169 2,589
  • USD 2,416 2,884

Until 02 Nov

  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

In your basket 

Reviews of IPI's Advanced Pharmacovigilance training course


Really good speaker, lots of examples of scenarios which helps. Allowed interaction between the delegates to discuss topics during exercises.

Mar 17 2021

Rebecca Brennan
Safety Advisor, Alliance Healthcare Ltd

Mar 17 2021

Inspiring speaker. I was very excited about all the anecdotes that he told. Overall a very rewarding course.

Helle Ribjerg
Global Safety Specialist, LEO Pharma

Mar 17 2021

Very good webinar. Well structured, interactive questions, small group, advanced topics (not easy to find elsewhere), competent speaker, good platform.

Bettina Isler
Medical Information Manager, OrPha Swiss GmbH

Sep 23 2020

Great

Sidse Schjøtz
Complinace Manager, ALK

Sep 23 2020

Very nice course - will recommend to colleagues

Tina Rishoej Clausen
Global Safety Specialist, LEO Pharma

Sep 23 2020

Good course and the leader was very clear in what he wanted to say. Exercises were fun..

Amrita Kang
drug safety scientist, GE healthcare

Sep 23 2020

Generally very good and good to have the anecdotes from real life.

Sanne Mathias
Head of Compliance, ALK

Sep 23 2020

Parts of the presentation especially Day 3 were informative as it was more tailored to my role. I enjoyed the talk of RMPs, PSURs and crisis management. A lot of basics however were covered in this 'advanced course' in the CT directive topic, would be nice just to state what's changed and what's not changed almost like presenting a gap analysis, instead of covering basic definitions such as definition of an SAE and SUSAR and investigator reporting timelines. There was a 2 minute discussion on Brexit related changes on Day 2 which could have been a formal session as a presentation as I found that very useful for my role.

Maria Sajid
Safety Evaluation Scientist, Eisai Europe Ltd

Sep 25 2019

Overall, the best seminar I've attended in format, topics, and speaker. I had hoped to learn about PV in general and all the different reporting requirements and report types – I learned much more than that. The speaker was great and I particularly liked the real-life stories and examples.

Jane Bateman
Senior Drug Safety Scientist, GE Healthcare

Sep 25 2019

I was hoping to get more knowledge about the topics listed in the course presentation and I actually got a lot more, as we were not only given information related to the legislation in force but also very useful examples of applicability and some non-compliance cases. The speaker is undoubtedly an expert in the field with excellent presentation skills of all the proposed topics, including the most complex ones from a regulatory point of view. His experience and his analytic method facilitated my understanding of some critical passages of the law.

Ilaria Gargano
Global Safety Specialist, Leo Pharma

Mar 25 2019

The speaker shared a lot of knowledge and experiences which put in context the regulation/expectations from agencies and made the course really interesting.

Audrey Dicaire-Lavigne
Pharmacovigilance Leader, Jubilant Draximage Inc.

Mar 25 2019

The speaker had really extensive knowledge and he was able to transmit all the topics in a very clear way.

Elena Jiménez Gutiérrez
Global Safety Professional, LEO Pharma

Mar 25 2019

Great presentations, great time keeping, good balance between exercises and presentations

Ida Mizera
Local Responsible Person for PV, Grunenthal Ltd

Mar 25 2019

Graeme has superb knowledge of the regulations and guidelines around pharmacovigilance and talks in a passionate and engaging manner. An excellent course that really gives the students a much better understanding of pharmacovigilance and the opportunity to share knowledge. The content was spot on and Graeme's presentation style was engaging.

Christopher Harper
Senior Medical Information Manager, Astellas Pharma Europe Ltd

Sep 25 2019

The speaker was able to make a dry topic really exciting and I particularly liked the interaction with the group.

Margot Börgartz
Stewardship Manager, Bayer AG

Sep 25 2019

[Graeme] was a very good presenter with very good industry knowledge and experience. Very interactive sessions and answered all our questions.

Smitha Bhat
Principal CMG Scientist, GlaxoSmithKline

Mar 25 2019

Very valuable with real examples. I liked that future elements of PV regulation were pointed out and not just the current one.

Dorthe Lundmark
Drug Safety Coordinator, Pharmacosmos A/S

Mar 25 2019

The content of the course was excellent for an all round view of PV, the presentations were good and flowed from one aspect of PV to another. Graeme's passion and energy for drug safety was evident throughout the three days. I really enjoyed this course.

Ciara Walsh
Head of Regulatory Affairs and Pharmacovigilance, Noden Pharma DAC

Mar 7 2018

Amazing for continuing to develop skills in PV to keep up with the regulatory expectations.

Maria Calvo Subirats
GCP&GVP Responsible (QA Unit), Ferrer Internacional

Mar 7 2018

The presenter managed to keep our attention and shared concrete examples, which helped us to clearly understand what's relevant.

Faouria Dervisagic
Drug Safety Associate, Idorsia Pharmaceuticals Ltd

Mar 7 2018

Was great, will support my work

Anette Wolfmeyer
Deputy QPPV (Qualified Person for Pharmacovigilance), Bayer Animal Health GmbH

Mar 7 2018

Excellent course - taught me from A to Z about PV. Content well coordinated to capture audience with different levels of PV experience. Excellent speaker. Highly recommended.

Suna Horner
Associate Medical Manager, HRA Pharma UK & IE Ltd.

Mar 7 2018

Very good speaker

Nicolas Vauche
Drug Safety Officer, AnticipSante

Mar 7 2018

This course provides a great opportunity to gain understanding of latest updated on the PV regulatory requirements and the expectation from regulatory inspectorate.

Maria Calvo Subirats
GCP&GVP Responsible (QA Unit), Ferrer Internacional

Sep 24 2018

A very knowledgeable and experienced speaker always ready to answer all the questions and give real-life examples.

Darya Pospíšilová
Pharmacovigilance Project Manager, Arriello

Sep 24 2018

The course was thorough and the manual a good resource to refer back to. The speaker had a very engaging presentation style and freely answered questions and shared real-word examples and inspection expectations.

Katy Blake
PV Specialist , Dexcel Pharma Limited

Sep 24 2018

A PV overview in three days, that's nice.

Tina Pank Vase
Associate Professional, LEO Pharma A/S

Mar 7 2018

Content, presentation and speaker were just great.

Wendy Kleijberg
QPPV, Baggerman Farma Consult

Mar 7 2018

It covers a lot of subjects, it was a complete course regarding activities in Pharmacovigilance. Presentation and speakers were really clean.

Gwladys Becuwe
Drug Safety Officer, Anticipsante

Sep 25 2017

Excellent

Olga Orlova
PV Process Manager, Bayer, JSC

Sep 25 2017

Good content and put into real life context

Tony Rigden
Head Of Regulatory & Pharmacovigilance, Chiesi UK LTD

Sep 25 2017

Very interesting and interactive course. Good training material and a competent trainer

Francesca Romana Borgia
PV QA Specialist & Auditor, Chiesi

Sep 25 2017

Graeme is clearly a PV Expert. The content of training gave a very good overview of all aspects of PV. Finally, a course that you can use in your daily work-life.

Thea Ellermann Petersen
Senior Pharmacovigilance Specialist, LEO Pharma

Mar 6 2017

Excellent

Mona Bjørkmo
Pharmacovigilance Scientist, GE Healthcare AS

Mar 6 2017

Very good (advanced) course

Peter Kohut
PV Specialist, Ewopharma International, s.r.o.

Mar 6 2017

Very experienced in many areas relevant for PV. Good examples. Open for questions and discussions.

Ingvild Haugen
PV Scientist, GE Healthcare

Mar 6 2017

Very good speaker with a wealth of knowledge. Good examples and real life stories. Would like other activities rather than pure listening.

Lisa Courtier
Drug Safety Officer, JensonR+ Limited

Sep 28 2016

Trainer is excellent

Murugan Addepalli
Senior Research Scientist, Sun Pharmaceutical Industries Ltd

Sep 28 2016

Content - highly relevant to my position. Presentation - enough detail and to the point. Speaker - very knowledgeable and engaging

Saha Jasarevic
Global Pharmacovigilance Scientist, GE Healthcare AS

Sep 28 2016

Overall a very positive experience, the course covers very current and relevant topics, is well organised and presenter is an engaging speaker

Rita Bildøy
PV Compliance and Training Expert, Ge Healthcare Lifesciences

Sep 28 2016

Really beneficial -Graeme is the best

Trine Allerslev
Senior Pharmacovigialnce Specialist, LEO Pharma

Sep 28 2016

I am really happy with all of it

Jelena Rebernisak
TPC Operations Coordinator, Pliva Croatia Ltd.

Sep 28 2016

More examples would be very helpful.

Jung Hyun Byun
PV Associate, Dong-A ST Co.,Ltd

UK

  • Abbott Healthcare Products Ltd
  • Actavis
  • Adamas Consulting Ltd
  • Alliance Healthcare Ltd
  • Almirall Limited
  • APC Pharma
  • Ark Therapeutics Ltd
  • Astellas Pharma Europe Ltd
  • AstraZeneca UK Ltd
  • Auden McKenzie Group
  • Biogen IDEC Ltd
  • Boehringer Ingelheim Ltd
  • Britannia Pharmaceuticals Ltd
  • British American Tobacco (Investments) Limited
  • Cancer Research UK
  • Cardinal Health
  • Celgene Europe Ltd
  • Chiesi Limited
  • Chiesi UK LTD
  • Chugai Pharma Europe Ltd
  • Dexcel Pharma Limited
  • Diamond Pharma Services
  • Eisai Europe Limited
  • Eisai Europe Ltd
  • Eisai Limited
  • Eli Lilly & Co Ltd
  • Ewopharma International s.r.o.
  • Forest Laboratories UK Ltd
  • Genethics Regulatory Services
  • Genus Pharmaceuticals Ltd
  • Gilead Science
  • Gilead Sciences
  • GlaxoSmithKline
  • Grunenthal Ltd
  • GW Pharmaceuticals
  • GW Pharmaceuticals plc
  • Hospira UK Limited
  • HRA Pharma UK & IE Ltd.
  • Icon Clinical Research (UK) Limited
  • Idis Limited
  • IDIS LTD
  • Innovata Ltd (part of Vectura Group plc)
  • Ipsen Biopharm Ltd
  • Janssen Cilag Ltd
  • Janssen-Cilag Ltd
  • JensonR+ Limited
  • Johnson & Johnson Consumer Services EAME Ltd
  • KKI
  • Kowa Research Europe Ltd
  • Liverpool School of Tropical Medicine
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Merck Serono Ltd
  • Merck Sharp & Dohme Ltd
  • Mercury Pharma Management Services Ltd
  • Mundipharma Research Ltd
  • Napp Pharmaceutical Group Ltd
  • Norgine Ltd
  • Norgine Ltd.
  • Novartis Pharmaceuticals UK Ltd
  • Novo Nordisk Ltd
  • Nycomed UK Limited
  • Ono Pharma UK Ltd
  • Parexel International Ltd
  • Perrigo
  • Pfizer Limited
  • Piramal Healthcare Ltd
  • Procter & Gamble Technical Centres Ltd
  • Proctor & Gamble Technical Centres Ltd
  • ProductLife Limited
  • ProductLife Ltd
  • Pure Drug Safety
  • Queen Anne Street Medical Cent
  • Ranbaxy Laboratories Ltd
  • RB
  • Reckitt Benckiser Healthcare (UK) Ltd
  • Roche
  • Roche Products Ltd
  • Roche Products Ltd.
  • Rosemont Pharmaceuticals
  • Rosemont Pharmaceuticals Limited
  • Sandoz Limited
  • SEQ Limited
  • Shire Pharmaceutical Ltd
  • Smith & Nephew Wound Management
  • Spectrum Regulatory Solutions
  • Stiefel Labs (Maidenhead) Ltd
  • Syntaxin Ltd
  • Takeda Development Centre Europe Ltd
  • Takeda UK Limited
  • Torbay Pharmaceuticals
  • UCB Pharma Limited
  • Valeant
  • VERIUS LTD
  • Warner Chilcott Pharmaceuticals UK Ltd
  • Winthrop Pharmaceuticals UK Ltd
  • Wyeth Pharmaceuticals

Denmark

  • Actavis A/S
  • AJ Vaccines A/S
  • ALK
  • ALK Abello A/S
  • Amgros
  • Astellas Pharma A/S
  • Ferring Pharmaceuticals A/S
  • H. Lundbeck A/S
  • Klifo
  • LEO Pharma
  • Leo Pharma A/S
  • LEO Pharrma
  • Novo Nordisk
  • Novo Nordisk A/S
  • Pharma Nord ApS
  • PharmaChem Consulting
  • Pharmacosmos A/S
  • Statens Serum Institut
  • Takeda Pharma A/S
  • VAN Pharma Consult

France

  • Amgen
  • AnticipSante
  • AnticipSante SAS
  • Besins Healthcare France
  • Boehringer Ingelheim France
  • Debioclinic SA
  • Ethypharm
  • Galderma R&D
  • Guerbet
  • Janssen
  • Johnson & Johnson
  • LABORATOIRE CHAUVIN / BAUSCH & LOMB
  • Orphan Europe
  • Pierre Fabre Medicament
  • SANOFI AVENTIS R & D
  • Sanofi Pasteur MSD
  • Sanofi Pasteur Siege mondial
  • Service Comptabilité
  • Stallergenes Greer plc

Germany

  • Abbott Laboratories GmbH
  • Abbott Products GmbH
  • BAYER AG
  • Bayer Animal Health GmbH
  • Bayer Pharma AG
  • Berlin-Chemie AG
  • Fresenius Kabi Oncology Limited
  • Grunenthal GmbH
  • Life Molecular Imaging GmbH
  • Merck KGaA
  • Merck Serono
  • MSD AH Innovation GmbH
  • Mundipharma Research GmbH & Co Kg
  • Mylan Healthcare GmbH
  • Schwarz BioSciences GmbH
  • Solvay Deutschland GmbH
  • UCB Pharma GmbH

Switzerland

  • Acino Pharma AG
  • Actelion Pharmaceutical Ltd
  • Basilea Pharmaceutica International Ltd
  • Celgene
  • Covis Pharma
  • CSL Behring AG
  • F. Hoffmann-La Roche Ltd
  • Ginsana SA
  • HPM (Geneva) SA
  • IBSA, Institut Biochimique SA
  • Idorsia Pharmaceuticals Ltd
  • Medicines for Malaria Venture
  • Novartis Pharma AG
  • OrPha Swiss GmbH
  • Roche Pharma (Switzerland) Ltd
  • SPEEDEL PHARMA LIMITED
  • Vifor SA

Ireland

  • Aspen Pharma Trading Ltd
  • Astellas Pharma
  • Chanelle Medical
  • Helsinn Birex Pharmaceuticals Ltd
  • Noden Pharma DAC
  • NorthStar Healthcare Ltd
  • Pfizer Limited
  • Pharmaceutical Development Ireland Limited
  • Pinewood Healthcare Ltd.
  • PPD
  • Shandon McGee Pharmacovigilance Company

United States of America

  • AEMS
  • Aeras Global TB Vaccine Foundation
  • Bausch & Lomb Inc
  • CareFusion
  • CEREXA INC
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Genentech Inc
  • Hoffmann-La Roche Incorporated
  • Medivation
  • OTSUKA MARYLAND RESEARCH INSTITUTE

Belgium

  • Amgen NV
  • Certor bvba
  • Colgate-Palmolive R&D
  • Glaxo Smithkline Biologicals
  • GlaxoSmithKline Vaccines
  • Janssen Pharmaceutica NV
  • Procter & Gamble Pharmaceuticals
  • SGS Belgium NV
  • SGS Belgium NV Life Science Services
  • UCB Pharma SA

Netherlands

  • Astellas BV
  • Baggerman Farma Consult
  • Baggerman Farma Consult B.V.
  • Dada Consultancy BV
  • Genzyme Europe BV
  • HAL Allergy BV Leiden
  • Interdos Pharma bv
  • Merck Sharp & Dohme
  • N V Organon

Spain

  • Almirall S.A.
  • Atlanta Agencia de Viajes S.A.
  • Bayer Hispania SL
  • Ferrer Internacional
  • Grupo Ferrer Internacional SA
  • Grupo Ferrer Internaional S.A.
  • Grupo Ferrer International
  • Laboratorios Almirall S A
  • PharmaMar

Italy

  • Recordati S.p.A.
  • Alfa Wassermann S.p.A.
  • Alfasigma spa
  • Alfrapharma Srl
  • Chiesi
  • Di Renzo SRL
  • Recordati S.p.A
  • Recordati S.p.A.

Sweden

  • AGA AB
  • AstraZeneca
  • AstraZeneca AB
  • AstraZeneca R&D Lund
  • Sanofi-aventis AB
  • SOBI
  • TFS, trial form support

Croatia

  • Agency for Medicinal Products and Medical Devices of Croatia (HALMED)
  • Belupo d.d.
  • Farmal D.D.
  • Pliva Croatia Ltd
  • Pliva Croatia Ltd.
  • Prime Vigilance doo Zagreb

Austria

  • Baxter AG
  • Baxter Innovations GmbH
  • Boehringer Ingelheim
  • Boehringer Ingelheim RCV GmbH & Co KG
  • Octapharma Pharmazeutika Produktionsges.m.b.H.

Czech Republic

  • Arriello
  • Arriello s.r.o.
  • PPD
  • Teva Czech Industries S R O
  • Zentiva ks

Romania

  • Actavis
  • Alvogen Romania SRL
  • Ewopharma AG
  • Romastru Trading Srl
  • Worwag Pharma GmbH & Co. KG

Canada

  • ApoPharma Inc
  • Jubilant Draximage Inc.
  • SHIRE CANADA
  • Theratechnologies inc

Israel

  • KAMADA
  • Kamada Ltd.
  • NeuroDerm
  • TEVA

Australia

  • CSL Biotherapies
  • CSL Limited
  • Roche Products Pty Ltd

Cyprus

  • Delorbis Pharmaceuticals Ltd
  • Genesis Pharma (Cyprus) Ltd
  • Medochemie Limited

Norway

  • GE Healthcare
  • GE Healthcare AS
  • Ge Healthcare Lifesciences

Russia

  • Bayer, JSC
  • Sanofi
  • Voyage Tour LLC

Saudi Arabia

  • mundipharma ksa
  • SAUDI FOOD & DRUG AUTHORITY
  • Saudi Food and Drug Authority

Turkey

  • Bayer Turk Kimya San. Ltd. Sti
  • Boehringer Ingelheim Ilaç Tic. A.S.
  • Nobel Ilac Sanayii ve Ticaret A.S A

Brazil

  • Amgen
  • AstraZeneca do Brasil Ltda.

India

  • Solvay Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd

Japan

  • Eisai Co. Ltd
  • Takeda Pharmaceutical Company Ltd

Serbia

  • PHARM-OLAM INTERNATIONAL LIMITED
  • Poslovni centar Hemofarm

Slovak Republic

  • Ewopharma International s.r.o
  • Ewopharma International, s.r.o.

South Africa

  • Aspen Pharmacare Holdings
  • DEPARTMENT OF HEALTH (SOUTH AFRICA)

United Arab Emirates

  • Gulf Pharmaceutical Industries
  • Pfizer Gulf FZ LLC

Bulgaria

  • Medica SA

Greece

  • Qualitis

Hungary

  • Celgene Kft

Korea, Democratic People's Republic Of

  • Dong-A ST Co.,Ltd

Korea, Republic Of

  • Green Cross Corp.

Malta

  • APL Swift Services (Malta) Ltd

Philippines

  • United Laboratories Inc

Portugal

  • Sanofi-Aventis SA

Slovenia

  • Medis, d.o.o.

Ukraine

  • Schering-Plough CE AG

Enrol now

Multiple colleagues?
Talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra BEER
Training expert

+44 (0)20 7749 4749

inhouse@ipi.academy